This is the current release of the guideline.

Definitions for the quality of the evidence (1-3) and strength of recommendation (A-E) are given at the end of the "Major Recommendations" field.

Which Patients Require Therapeutic Administration of Antimicrobials?

• Bowel injuries due to penetrating, blunt, or iatrogenic trauma that are repaired within 12 h and intraoperative contamination of the operative field by enteric contents under other circumstances should be treated with antibiotics for <24 h (A-1).
• For acute perforations of the stomach, duodenum, and proximal jejunum in the absence of antacid therapy or malignancy, therapy is also considered to be prophylactic (B-2).
• Similarly, acute appendicitis without evidence of gangrene, perforation, abscess, or peritonitis requires only prophylactic administration of inexpensive regimens active against facultative and obligate anaerobes (A-1).
• Acute cholecystitis is often an inflammatory but noninfectious disease. If infection is suspected on the basis of clinical and radiographic findings, urgent intervention may be indicated, and antimicrobial therapy should provide coverage against Enterobacteriaceae (B-2).
• Coverage against anaerobes is warranted in treatment of patients with previous bile duct–bowel anastomosis (C-3).
• If a patient with diagnosed infection has previously been treated with an antibiotic, that patient should be treated as if he or she had a health care–associated infection (B-3).

Selection of Empirical Antibiotic Treatment

• Antibiotics used for empirical treatment of community-acquired intra-abdominal infections should, therefore, be active against enteric gram-negative aerobic and facultative bacilli and beta-lactam–susceptible gram-positive cocci (A-1).
• Coverage against obligate anaerobic bacilli should be provided for distal small-bowel and colon-derived infections and for more proximal gastrointestinal perforations when obstruction is present (A-1).
• Agents that are used to treat nosocomial infections in the intensive care unit should not be routinely used to treat community-acquired infections (B-2).
• For patients with mild-to-moderate community-acquired infections, agents that have a narrower spectrum of activity, such as ampicillin/sulbactam, cefazolin or cefuroxime/metronidazole, ticarcillin/clavulanate, and ertapenem are preferable to more costly agents that have broader coverage against gram-negative organisms and/or greater risk of toxicity (A-1).
• Aminoglycosides have relatively narrow therapeutic ranges and are associated with ototoxicity and nephrotoxicity. Because of the availability of less toxic agents demonstrated to be of equal efficacy, aminoglycosides are not recommended for routine use in community-acquired intra-abdominal infections (A-1).
• Individualized administration of aminoglycosides is the preferred dosing regimen for patients receiving these agents for intra-abdominal infections (A-1).
• Completion of the antimicrobial course with oral forms of a quinolone plus metronidazole (A-1) or with oral amoxicillin/clavulanic acid (B-3) is acceptable for patients who are able to tolerate an oral diet.

Identification of High-risk Patients

• Patients with other acute and chronic diseases may also have immunosuppression, although this is difficult to define. For such patients, use of antimicrobial regimens with expanded spectra may be warranted, including meropenem, imipenem/cilastatin, piperacillin/tazobactam, ciprofloxacin plus metronidazole, or a third- or fourth-generation cephalosporin plus metronidazole (C-3).
• Prolonged preoperative length of stay and prolonged (>2 days) preoperative antimicrobial therapy are significant predictors of antimicrobial failure leading to recurrent infection and suggest that organisms resistant to the empirical antimicrobial regimen may be responsible for infection. Such patients should be treated for nosocomial infection, as detailed in Health Care–Associated Intra-abdominal Infections (C-3).

Duration of Therapy

• For patients who have persistent or recurrent clinical evidence of intra-abdominal infection after 5 to 7 days of therapy, appropriate diagnostic investigation should be undertaken. This should include computed tomography (CT) or ultrasonographic imaging, and antimicrobial therapy effective against the organisms initially identified should be continued (C-3).

Laboratory Considerations

• For intra-abdominal infections, particularly those involving the colon, failure rates are substantially higher if empirical therapy is not active against any identified isolate. Altering the regimen to cover identified isolates improves outcome (C-3).

Health Care-associated Intra-abdominal Infections

• In infections occurring after elective or emergent operations, a more resistant flora is routinely encountered. Furthermore, there is evidence that not providing empirical therapy active against the subsequently identified pathogens is associated with significant increases in mortality and treatment failure (C-3).

What Material Should Be Sent for Culture?

• Blood cultures do not provide additional clinically relevant information for patients with community-acquired intra-abdominal infections and are, therefore, not recommended for such patients (A-1).

When Should Gram Staining be Performed?

• For community-acquired infections, there is no value in making a Gram stain of the infected material (B-2).

Indications for Anti-fungal Therapy

• Even when fungi are recovered from patients, antifungal agents are unnecessary, unless the patient has recently received immunosuppressive therapy for neoplasm, transplantation, or inflammatory disease or has postoperative or recurrent intra-abdominal infection (B-2).
• Anti-infective therapy for Candida should be withheld until the infecting species is identified (C-3).
• If C. albicans is found, fluconazole is an appropriate choice (B-2).
• For fluconazole-resistant Candida species, therapy with amphotericin B, caspofungin, or voriconazole is appropriate (B-3).
• Caspofungin and voriconazole cause substantially less toxicity than does amphotericin B and are specifically indicated for patients with renal dysfunction (A-1).

Indications for Antienterococcal Therapy

• Routine coverage against Enterococcus is not necessary for patients with community-acquired intra-abdominal infections (A-1).
• Antimicrobial therapy for enterococci should be given when enterococci are recovered from patients with health care–associated infections (B-3).

Quality of Evidence

1. Evidence from >1 properly randomized, controlled trial
2. Evidence from >1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from >1 center); from multiple time-series; or from dramatic results from uncontrolled experiments
3. Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

Strength of Recommendation

1. Good evidence to support a recommendation for use
2. Moderate evidence to support a recommendation for use
3. Poor evidence to support a recommendation
4. Moderate evidence to support a recommendation against use
5. Good evidence to support a recommendation against use

None provided

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

Not applicable: The guideline was not adapted from another source.

2003 Oct 15

Infectious Diseases Society of America - Medical Specialty Society

Infectious Diseases Society of America (IDSA)

Not stated

Committee Members: Joseph S. Solomkin, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH; John E. Mazuski, Department of Surgery, Washington University School of Medicine, St. Louis, MO; Ellen J. Baron, Department of Microbiology, Stanford University School of Medicine, Palo Alto, CA; Robert G. Sawyer, Department of Surgery, University of Virginia, Charlottesville; Avery B. Nathens, Department of Surgery, University of Washington, Seattle; Joseph T. DiPiro, University of Georgia College of Pharmacy, and Department of Surgery, Medical College of Georgia, Augusta; Timothy Buchman, Department of Surgery, Washington University School of Medicine, St. Louis, MO; E. Patchen Dellinger, Department of Surgery, University of Washington, Seattle; John Jernigan, Centers for Disease Control and Prevention, Atlanta, GA; Sherwood Gorbach, Department of Medicine, Tufts University School of Medicine, Boston, MA; Anthony W. Chow, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; John Bartlett, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Joseph S. Solomkin has received honoraria and travel expenses for consulting services from Merck, Ortho-McNeill, Pfizer, Bayer, and AstraZeneca.

John E. Mazuski has received honoraria and travel expenses as a speaker for Wyeth Pharmaceuticals and as a consultant for Merck. He has been an investigator in research sponsored by Wyeth Pharmaceuticals, Bayer, Pfizer, and AstraZeneca Pharmaceuticals.

Ellen Jo Baron has been a consultant with travel and honoraria provided by Ortho-McNeil, Bayer, Merck, and AstraZeneca Pharmaceuticals. Former research projects have been funded by Merck, Pfizer, and Bristol-Myers Squibb. She owns >$10,000 worth of stock in Merck.

Robert G. Sawyer has received honoraria and travel expenses as a consultant for Pfizer and Merck.

Avery B. Nathens has received honoraria and travel expenses for consulting services from Merck, Pfizer, and Wyeth.

Joseph T. DiPiro has received honoraria and travel expenses for consulting services for Merck.

Timothy Buchman has served as a local site investigator in clinical trials sponsored by Bayer and AstraZeneca.

E. Patchen Dellinger has received honoraria and travel expenses for consulting services from Merck, Ortho-McNeill, Pfizer, Bayer, Wyeth, and AstraZeneca.

Sherwood Gorbach has received honoraria and travel expenses for consulting services from Bayer.

Anthony W. Chow has received honoraria and travel expenses for consulting services from Ortho-McNeill, Pfizer, Bayer, and AstraZeneca Pharmaceuticals.

This is the current release of the guideline.

None available

This NGS summary was completed by ECRI on May 6, 2004. This summary was updated by ECRI on February 21, 2006 following the U.S. Food and Drug Administration (FDA) advisory on Tequin (gatifloxacin). This summary was updated by ECRI Institute on October 3, 2007 following the U.S. Food and Drug Administration (FDA) advisory on Rocephin (ceftriaxone sodium). This summary was updated by ECRI Institute on July 28, 2008 following the U.S. Food and Drug Administration advisory on fluoroquinolone antimicrobial drugs.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.